On July 24, the U.S. Food and Drug Administration (FDA) approved Praluent (alirocumab) injection, the first cholesterol-lowering treatment approved in a new class of drugs known as proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors. Read more.
Most Recent Content
For Nurse Practitioners
Quiz: Migraines and Hormones
Women are 2 to 3 times more likely than men to have migraines. Decades ago, these were attributed to women’s inability to cope with...
